世界のハンチントン病市場 – 2030 年までの業界動向と予測

ハンチントン病市場分析と規模

ハンチントン病は北米で約 3 万人が罹患しており、有病率は 10 万人あたり 5.7 人です。小児ではそれほど一般的ではありません。ハンチントン病は、疾患修飾薬が市場環境を一変させるため、今後数年間で大幅な発展が見込まれています。この疾患に関する最新の研究は、主に免疫調節療法、遺伝子治療 (アンチセンス オリゴヌクレオチド、mRNA スプライシング、マイクロ RNA (miRNA)、ジンクフィンガー DNA 結合タンパク質 (ZFP) を使用) などのいくつかの新しい治療法の使用に焦点を当てています。  

データブリッジ市場調査は、2023年から2030年の予測期間におけるハンチントン病市場の成長率を分析しています。ハンチントン病市場の予想CAGRは、上記の予測期間において約20.1％になる傾向があります。市場は2022年に4億3,470万米ドルと評価され、2030年までに1億8,163万米ドルまで成長すると予想されています。市場価値、成長率、市場セグメント、地理的範囲、市場プレーヤー、市場シナリオなどの市場洞察に加えて、データブリッジ市場調査チームがまとめた市場レポートには、詳細な専門家分析、患者の疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

ハンチントン病市場の範囲とセグメンテーション

Market Definition

Huntington’s disease is a rare type of inherited disease which causes progressive breakdown  of nerve cells in the brain, majorly affecting physical movements, emotions and cognitive abilities. The symptoms associated with this disease can appear at any time but typically appear at 30-40 years old. If the condition appears before 20 years of age, this disorder is considered to be juvenile Huntington’s disease.

Huntington’s Disease Market Dynamics

Drivers

• Increasing Prevalence of Huntington’s Disease

Huntington’s Disease (HD) is a progressive neurological condition that is caused by CAG expansions in the Huntingtin (Htt) gene. It affects around 1 out of every 10,000 people in the U.S. Healthy people mostly have less than 35 CAG repetitions, on the other hand, HD patients have CAG expansions that ranges from 36 to 200. The frequency varies by more than 10-fold between different geographical locations, that can be associated to variations in case ascertainment and diagnostic criteria.  

• Growing Demand For Disease-Modifying Therapies

The disease-modifying therapies segment is projected to witness the huge growth during the forecast period. This is due to an increase in R&D for disease-modifying therapy and the rising demand for advanced products, such as gene therapy and stem cell therapy. The government initiatives such as Fast Track Designation by the U.S. FDA for increasing the registration process may surge the market in the upcoming years. For instance, in 2021 in the month of September, U.S. FDA granted fast track designation to Sage Therapeutics’s drug, SAGE-718, as a budding treatment for Huntington’s disease.

Opportunities

• Increased Clinical Research Activities

There have been growing clinical research activities for numerous drug development processes that are boosting the market's growth. For instance, Annexon, Inc. is engaged in the development of ANX005-an experimental monoclonal antibody that targets abnormal C1q activity in complement-mediated neurodegenerative diseases, such as huntington’s disease. This is administered intravenously (IV) and is meant to suppress C1q. Additionally, in November 2020, the company initiated a phase 2 clinical trial of ANX005 used for the treatment of HD patients. Stem cell therapy is also causing interest as a potential treatment for HD. Cellavita, in collaboration with AzidusPharma, is currently investigating stem cell therapy, CELLAVITA-HD in phase 2/ 3 ADORE-DH trial.   

• Increasing Drug Approvals

There have been growing drug approvals for the treatment of HD patients. For instance, in May 2020, Teva Pharmaceutical Industries Ltd. received NMPA approval for Austedo in China for treating cholera associated with Huntington’s disease. This huge expansion of the company is anticipated to increase the patient base and the revenue growth.

 Restraints/Challenges

• Limited Availability of Drugs

The number of approved drugs for Huntington’s disease are limited because of strict policies and regulations. This is anticipated to impede the market growth during the forecast period. Furthermore, the lack of awareness about this disorder in major parts of the world is estimated to restrict the growth of huntington’s disease market.

• Discontinuation of Drug Trials

The drug development for the disease has faced severe obstacles as several therapies have failed to demonstrate efficacy or were related with major toxicity. For instance, in March 2021, F. Hoffmann-La Roche Ltd. discontinued the dosing in the phase III GENERATION HD1 study of tominersen in manifest HD. This conclusion was made on the basis of findings of an unblinded Independent Data Monitoring Committee's (iDMC) pre planned examination of data from the phase III research.

This Huntington’s disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Huntington’s disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Huntington’s Disease Market

During the COVID-19 pandemic, the sales of off-label drugs such as antipsychotics, anti-depressants, and anticonvulsant were done through numerous online pharmacies to manage symptoms associated with the disease. The conduction of clinical trials was delayed because of the government-imposed lockdown during the COVID-19 pandemic.

In the post pandemic era, many of hospitals and clinics worldwide reported that clinical visits frequency for the diagnosis and treatment of HD has improved. Consequently, the market will grow with the projected growth rate. The clinical trials for Huntington’s disease development have increased post-pandemic.

Recent Developments:

• In 2021, NeuExcell Therapeutics Inc collaborated with Spark Therapeutics, Inc. to develop gene therapy for the treatment of HD. Under the agreement, NeuExcell Therapeutics is meant to receive upfront license fees, R&D, and sales milestone payments of up to approximately USD 190 million and additional product royalties.

Global Huntington’s Disease Market Scope

The Huntington’s disease market is segmented on the basis of diagnosis, treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

• MRI
• CT Scan
• Genetic Testing
• Others

Treatment Type

• Symptomatic Therapy
• Disease-Modifying Therapy
• Others

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

 Huntington’s Disease Market Regional Analysis/Insights

The Huntington’s disease market is analyzed and market size insights and trends are provided by diagnosis, treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the Huntington’s disease market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific will be expecting positive growth for Huntington’s disease market throughout the forecasted period due to the continuously increasing population resulting increasing prevalence of CNS related disorders.  

North America dominates the market due to increased demand of CNS disorders treatment and research undertaken by several companies.

レポートの国別セクションでは、市場の現在および将来の動向に影響を与える国内市場における個別の市場影響要因と規制の変更についても説明しています。また、国別データの予測分析を提供しながら、グローバルブランドの存在と入手可能性、地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、国内関税と貿易ルートの影響も考慮されています。   

競争環境と世界のハンチントン病市場シェア分析

ハンチントン病市場の競争状況では、競合他社ごとに詳細が提供されます。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性が含まれます。提供されている上記のデータ ポイントは、ハンチントン病市場に関連する会社の焦点にのみ関連しています。

ハンチントン病市場で活動している主要企業は次のとおりです。

• テバ製薬工業株式会社（イスラエル）
• アムニール・ファーマシューティカルズLLC（米国）
• エレクタAB（スウェーデン）
• アルニラム・ファーマシューティカルズ（米国）
• アポテックス株式会社（カナダ）
• アルマタ・ファーマシューティカルズ社（米国）
• ファイザー社（米国）
• H. ルンドベック A/S (デンマーク)
• アルテリティ・セラピューティクス（オーストラリア）
• バーテックス・ファーマシューティカルズ・インコーポレーテッド（米国）
• SK Plc.（英国）
• セレジーン社（米国）
• ソムバイオテック（スペイン）
• パロビオファーマ （スペイン）
• イプセンファーマ（フランス）

SKU-59170